|
1
|
Lombardo LJ, Lee FY, Chen P, Norris D,
Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM,
et al: Discovery of
N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor
activity in preclinical assays. J Med Chem. 47:6658–6661. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rix U, Hantschel O, Dürnberger G, Rix LL
Remsing, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P,
Colinge J, et al: Chemical proteomic profiles of the BCR-ABL
inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase
and nonkinase targets. Blood. 110:4055–4063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Oers NS, Killeen N and Weiss A: Lck
regulates the tyrosine phosphorylation of the T cell receptor
subunits and ZAP-70 in murine thymocytes. J Exp Med. 183:1053–1062.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meignin V, de Latour R Peffault, Zuber J,
Régnault A, Mounier N, Lemaître F, Dastot H, Itzykson R, Devergie
A, Cumano A, et al: Numbers of Foxp3-expressing CD4+CD25high T
cells do not correlate with the establishment of long-term
tolerance after allogeneic stem cell transplantation. Exp Hematol.
33:894–900. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D,
Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ and Ritz
J: Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in
patients with chronic graft-versus-host disease. Blood.
106:2903–2911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Theil A, Tuve S, Oelschlägel U, Maiwald A,
Döhler D, Oßmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, et
al: Adoptive transfer of allogeneic regulatory T cells into
patients with chronic graft-versus-host disease. Cytotherapy.
17:473–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bluestone JA, Trotta E and Xu D: The
therapeutic potential of regulatory T cells for the treatment of
autoimmune disease. Expert Opin Ther Targets. 19:1091–1103. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Demirkiran A, Hendrikx TK, Baan CC and van
der Laan LJ: Impact of immunosuppressive drugs on CD4+CD25+FOXP3+
regulatory T cells: Does in vitro evidence translate to the
clinical setting? Transplantation. 85:783–789. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoffmann P, Ermann J, Edinger M, Fathman
CG and Strober S: Donor-type CD4(+)CD25(+) regulatory T cells
suppress lethal acute graft-versus-host disease after allogeneic
bone marrow transplantation. J Exp Med. 196:389–399. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trenado A, Charlotte F, Fisson S, Yagello
M, Klatzmann D, Salomon BL and Cohen JL: Recipient-type specific
CD4+CD25+ regulatory T cells favor immune reconstitution and
control graft-versus-host disease while maintaining
graft-versus-leukemia. J Clin Invest. 112:1688–1696. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Savani BN, Montero A, Kurlander R, Childs
R, Hensel N and Barrett AJ: Imatinib synergizes with donor
lymphocyte infusions to achieve rapid molecular remission of CML
relapsing after allogeneic stem cell transplantation. Bone Marrow
Transplant. 36:1009–1015. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weisser M, Tischer J, Schnittger S, Schoch
C, Ledderose G and Kolb HJ: A comparison of donor lymphocyte
infusions or imatinib mesylate for patients with chronic
myelogenous leukemia who have relapsed after allogeneic stem cell
transplantation. Haematologica. 91:663–666. 2006.PubMed/NCBI
|
|
13
|
Chunduri S, Dobogai LC, Bruno A, Kadkol S
and Rondelli D: Does post-transplant treatment with imatinib
mesylate inhibit graft-versus-leukemia? Leukemia. 19:456–457. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Rezende LC, Silva IV, Rangel LB and
Guimarães MC: Regulatory T cell as a target for cancer therapy.
Arch Immunol Ther Exp (Warsz). 58:179–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Larmonier N, Janikashvili N, LaCasse CJ,
Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B and
Katsanis E: Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell
activity and enhances active immunotherapy against BCR-ABL- tumors.
J Immunol. 181:6955–6963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fei F, Yu Y, Schmitt A, Rojewski MT, Chen
B, Götz M, Döhner H, Bunjes D and Schmitt M: Dasatinib inhibits the
proliferation and function of CD4+CD25+ regulatory T cells. Br J
Haematol. 144:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fei F, Yu Y, Schmitt A, Rojewski MT, Chen
B, Greiner J, Götz M, Bunjes D and Schmitt M: Effects of nilotinib
on regulatory T cells: The dose matters. Mol Cancer. 9:222010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shah K, Parikh S and Rawal R: Tyrosine
kinase inhibitors in Ph+ chronic myeloid leukemia therapy: A
review. Asian Pac J Cancer Prev. 17:3025–3033. 2016.PubMed/NCBI
|
|
20
|
Hughes TP, Hochhaus A, Branford S, Müller
MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien
SG, et al: Long-term prognostic significance of early molecular
response to imatinib in newly diagnosed chronic myeloid leukemia:
An analysis from the International Randomized Study of Interferon
and STI571 (IRIS). Blood. 116:3758–3765. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seggewiss R, Loré K, Greiner E, Magnusson
MK, Price DA, Douek DC, Dunbar CE and Wiestner A: Imatinib inhibits
T-cell receptor-mediated T-cell proliferation and activation in a
dose-dependent manner. Blood. 105:2473–2479. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schade AE, Schieven GL, Townsend R,
Jankowska AM, Susulic V, Zhang R, Szpurka H and Maciejewski JP:
Dasatinib, a small-molecule protein tyrosine kinase inhibitor,
inhibits T-cell activation and proliferation. Blood. 111:1366–1377.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Das J, Chen P, Norris D, Padmanabha R,
Linc J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, et al:
2-Aminothiazole as a novel kinase inhibitor template.
Structure-activity relationship studies toward the discovery of
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-
piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carbox-amide
(dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med
Chem. 49:6819–6832. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blake SJ, Lyons AB and Hughes TP:
Nilotinib inhibits the Src-family kinase LCK and T-cell function in
vitro. J Cell Mol Med. 13:599–601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mustjoki S, Lundán T, Knuutila S and
Porkka K: Appearance of bone marrow lymphocytosis predicts an
optimal response to imatinib therapy in patients with chronic
myeloid leukemia. Leukemia. 21:2363–2368. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fontenot JD and Rudensky AY: A well
adapted regulatory contrivance: Regulatory T cell development and
the forkhead family transcription factor Foxp3. Nat Immunol.
6:331–337. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Geiger TL and Sharyn T: Nature and nurture
in Foxp3(+) regylatory T cell development, stability, and function.
Hum Immunol. 73:232–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miyara M, Yoshioka Y, Kitoh A, Shima T,
Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al:
Functional delineation and differentiation dynamics of human CD4+ T
cells expressing the FoxP3 transcription factor. Immunity.
30:899–911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimizu J, Yamazaki S, Takahashi T, Ishida
Y and Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells
through GITR breaks immunological self-tolerance. Nat Immunol.
3:135–142. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suri-Payer E and Cantor H: Differential
cytokine requirements for regulation of autoimmune gastritis and
colitis by CD4(+)CD25(+) T cells. J Autoimmun. 16:115–123. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen X, Du Y, Lin X, Qian Y, Zhou T and
Huang Z: CD4+CD25+ regulatory T cells in tumor immunity. Int
Immunopharmacol. 34:244–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
